CA Patent

CA3012607A1 — Crispr enzymes and systems

Assigned to Skolkovo Institute of Science and Technology · Expires 2016-12-22 · 9y expired

What this patent protects

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non -naturally occurring or engineered DNA or RNA- targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one t…

USPTO Abstract

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non -naturally occurring or engineered DNA or RNA- targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.

Drugs covered by this patent

Patent Metadata

Patent number
CA3012607A1
Jurisdiction
CA
Classification
Expires
2016-12-22
Drug substance claim
No
Drug product claim
No
Assignee
Skolkovo Institute of Science and Technology
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.